Identification of potential biomarkers for CAD using integration with expression and methylation data and validation by case-control study

CURRENT STATUS: POSTED

Xiaokang Zhang
Wuhan University Zhongnan Hospital

Yang Xiang
Wuhan University Zhongnan Hospital

Dingdong He
Wuhan University Zhongnan Hospital

Bin Liang
Wuhan University Zhongnan Hospital

Chen Wang
Wuhan University Zhongnan Hospital

Jing Luo
Wuhan University Zhongnan Hospital

Fang Zheng
Wuhan University Zhongnan Hospital

zhengfang@whu.edu.cn Corresponding Author

DOI: 10.21203/rs.2.23331/v1

SUBJECT AREAS
Translational Medicine

KEYWORDS
Coronary artery disease, methylation, FN1, PTEN, POLR3A
Abstract
Background: DNA methylation plays an essential role in the pathogenesis of coronary artery disease (CAD) through regulating mRNA expressions. This study aimed to identify hub genes as biomarkers functioning in CAD and regulated by DNA methylation.

Methods: Gene expression and methylation datasets of peripheral blood leukocytes (PBLs) of CAD were downloaded from Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) and differentially methylated genes (DMGs) were identified based on differentially methylated CpG sites (DMCs) in intragenic regions. The overlapped genes in DEGs and DMGs were filtered and defined as differentially expressed-methylated genes (DEMGs). Multiple computational approaches were performed to analyze the regulatory networks of DEMGs and recognize hub genes, subsequently. Finally, top hub genes were verified in a case-control study based on their differential expression levels between CAD cases and controls.

Results: Totally 535 DEMGs were identified and partitioned into 4 subgroups. TSS200 and 5’UTR were confirmed as high enrichment areas of DMCs. DEMGs mainly enriched in processes of histone H3-K27 methylation, regulation of posttranscription and DNA-directed RNA polymerase activity. Pathway enrichment showed DEMGs participated in VEGF signaling pathway, adipocytokine signaling pathway and PI3K-Akt signaling pathway. Besides, hub genes FN1 (fibronectin 1), PTEN (phosphatase and tensin homolog), POLR3A (RNA polymerase III subunit A) were experimentally proved discordantly expressed in CAD patients when compared with controls.

Conclusions: In conclusion, our study demonstrated the probable functional genes of PBLs in CAD, in which FN1, PTEN and POLR3A were confirmed. The underlying mechanism that differential expression-methylation of FN1, PTEN and POLR3A in CAD need further study.

Background
Coronary artery disease (CAD), as the main type of cardiovascular diseases, has become one of the leading causes of morbidity and mortality in both developed and developing countries [1]. And the circumstance shows an acuter tendency recently due to the population aging. According to the CAD prediction model, more than 20 million deaths and 16 million labor loss will be attributed to CAD from
2000 to 2029 in China [2]. The total social economy devotion to CAD in developing countries was estimated to approximately 3.7 trillion dollars in 2010, which is roughly equal to 1–3% of Gross Domestic Product (GDP) across developing countries [3].

Coronary arteriography (CAG) is the gold standard of CAD diagnosis, but the high cost and invasiveness limit its application [4]. Whereas, the cheaper cost and less invasive detection make blood biomarkers easier in promotion [5]. Epigenetics is defined as the heritable posttranscriptional modifications that are not induced by the nucleotide sequence alterations of DNA [6]. Multiple factors such as environment, diet, oxidative stress and inflammatory stimuli, have influence on epigenetics contents, which including DNA methylation, RNA methylation, chromatin histone modification, and non-coding RNA, and DNA methylation is the most indagated [7].

Aberrant DNA methylation participates in various processes of CAD development by regulating mRNA expression of interrelated genes. For instance, ABCA1 plays an essential part in reverse cholesterol transport (RCT) by promoting the excretion of free cholesterol and phospholipids from cells [8]. The alternative hypermethylation of ABCA1 promotor has been verified to be related with the high expression of ABCA1, which can accelerate the process of CAD by expediting the formation of foam cells [9–10]. Furthermore, cystathionine gamma-lyase, encoded by CTH, is a crucial part of the homocysteine metabolism pathway [11]. Previous studies have found that hypermethylation of CTH promotor in hyperhomocysteinemia mouse can lead to the decrease of CTH expression, which in turn prevents homocysteine from being catabolized and causes vascular endothelial cells injury, eventually results in CAD [12–13]. In the past a few years, numbers of researches on DNA methylation mainly focused on the connection between methylation condition of promter regions and the expression level of related genes. Nevertheless, the aberrant methylation status of other gene regions has also been identified to be associated with CAD and the complex regulation networks remain largely unexplored [14–16].

To the best of our knowledge, an integrative research that combined both mRNA expression and DNA methylation microarrays of PBLs in CAD in Chinese was required. In our study, we calculated the methylation status of 5’-C-phosphate-G-3’ (CpGs) sites in different intragenic gene regions, including
TSS1500, TSS200, 5'UTR, 1stExon, body, and 3'UTR. Besides, we consolidated DNA methylation and mRNA expression data in order to recognize genes functioning in CAD and associated with DNA methylation, which might be potential PBLs biomarkers. We identified hub genes that were both aberrantly methylated and differentially expressed in CAD patients compared with controls. Vital hub genes were validated in a case-control study to enhance the reliability of bioinformatics analysis. Through combination of bioinformatics analysis and clinical sample validation, we aimed to ascertain novel feasible PBLs biomarkers and shed light on potential mechanisms in the pathogenesis of CAD.

Methods
The methods used in our study mainly contained microarray data collection, differential expression and methylation analysis, functional and pathway enrichment analysis, PPI network establishment, module analysis and hub genes identification, followed by quantitative real-time PCR (qPCR) validation in PBLs, correlation analysis and multivariate stepwise linear regression analysis. The research flow diagram of this study is shown in Additional file 1: Fig. S1.

Microarray Data Collection
We retrieved GEO of The National Center for Biotechnology Information (NCBI) to screen datasets that contained profiling information about mRNA expressions and DNA methylations in CAD patients versus controls. A series of datasets were obtained and only those that met both the inclusion and exclusion criteria were analyzed subsequently. The detailed inclusion criteria were as followed: (1) datasets involved mRNA expression information or DNA methylation status detected from PBLs; (2) contained both CAD patients and controls; (3) sample size was no less than 5 of each subgroup. Besides, datasets were excluded if specimen type was one of the components of PBLs, such as monocyte, granulocyte or platelet. Only two datasets were up to the selection criteria, GSE42148 and GSE107143. Gene expression profiling array (GSE42148), measured by the Agilent-028004 SurePrint G3 Human GE 8 x 60K Microarray, provided mRNA expression data from 11 controls with normal electrocardiogram diagnoses and 13 CAD patients. The series matrix and platform files (GPL13607) were downloaded from GEO database. Genome-wide DNA methylation profiling array (GSE107143) contained information of DNA methylation status from 8 controls with normal physical condition and 8
CAD patients. The data were measured by Illumina HumanMethylation450 BeadChip and the series matrix file as well as the platform file (GPL13534) were obtained from GEO database. Besides, in consideration of mRNA expression array GSE71226 didn’t meet the inclusion criteria with a small sample size of 3 CAD patients and 3 controls, we used it only to evaluate the discriminating ability of candidate gene mining.

Differential Expression Analysis
The R package named “limma” was utilized to select differentially expressed genes (DEGs) from the series matrix file downloaded from GEO database [17]. Probes without matching gene symbols were deleted and genes with multiple probes were averaged in the subsequent analysis. We took $P < 0.05$ and absolute value of $\log_2 FC$ (fold change) $> 0.3$ as threshold of significant DEGs. The heatmap based on the expression data was drawn using the R package “pheapmap”.

Differential DNA Methylation Analysis
AS one of the mainstream detection platforms for DNA methylation, Illumina HumanMethylation450 BeadChip covers roughly 450,000 CpGs that randomly separate in different gene regions, including TSS1500, TSS200, 5′UTR, 1stExon, body, 3′UTR, and regions between adjacent genes. TSS1500 and TSS200 are regions from 201 to 1500 bases and 1 to 200 bases of the upstream of transcriptional start site (TSS), respectively. The “5′UTR (5’ untranslated region)” is considered as the region between TSS and the first initiation codon. “1stExon (the first exon)” is one of the most extensively studied translated regions that is deemed to be influenced by the methylation status generally. “Body” stands for the sequence from the first initiation codon to the stop codon of a gene. The “3′UTR (3’ untranslated region)” is the area between stop codon and poly-A tail. The 6 intragenic regions mentioned above are the main components of a gene and we took the average of the beta value of CpGs from the same region as the comprehensive methylation level of each intragenic region. The limma package of R was used for identification of differentially methylated CpGs sites (DMCs), differentially methylated regions (DMRs), and differentially methylated genes (DMGs) with the threshold $P < 0.05$ and $\log_2 FC > 0.3$. Single CpGs met the threshold were taken as DMCs, meanwhile, intragenic regions matched the threshold were identified as DMRs. Genes with one or more DMRs that
differentially methylated in the same direction were considered as DMGs. We defined genes that were identified both as DEGs and DMGs as differentially expressed-methylated genes (DEMGs). The Upset plot performed by R package “UpSetR” was utilized to describe the distribution of DMCs in different intragenic regions [18]. The locations of DMCs on chromosomes were visualized by R package “Rideogram” [19].

**Functional And Pathway Enrichment Analysis**

R package “clusterProfiler” was resorted to implement Gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis [20, 21]. More precisely, GO enrichment analysis was carried out within 3 classical subschemas: biological process (BP), cellular component (CC), and molecular function (MF). Subsequently, we utilized “ggplot2”, one of the most extensively cited R packages, for visualization of the analysis results. The cutoff value of statistical significance was set as P < 0.05.

**PPI network establishment, module analysis and hub genes identification**

Protein-protein interaction (PPI) network was preliminarily constructed through Search Tool for the Retrieval of Interacting Genes (STRING) database to explore the inherent relation and regularity of DEMGs. The cutoff value of interaction score in STRING database was set at 0.4. To make the PPI network more legible, we resorted Cytoscape to visualize the network based on interaction information calculated from STRING [22]. An auxiliary application named Molecular Complex Detection (MCODE) from Cytoscape was used for module analysis to identify modules with significant interaction under threshold MCODE scores > 3, k-score = 2 and nodes numbers > 4. CytoHubba, another frequently-used application from Cytoscape, provided 12 algorithms to estimate evidence levels of interaction within genes from PPI network [23]. We took summation of these 12 evaluation scores as the comprehensive assessment standard for screening top hub genes.

**Study Population And PBLs Collection**

We performed a case-control study to consolidate the expression status of hub genes filtered through bioinformatics analysis. PBLs of 30 CAD patients from Zhongnan Hospital of Wuhan University (Wuhan, China) were collected during December 2018 and July 2019. The diagnostic criterion for CAD was based on coronary angiography that showing stenosis caused by atherosclerotic plaque was
more than 50% in at least one coronary artery. Meanwhile, 30 age and sex matched people who were negative in examination of ultrasound or coronary CTA or coronary angiography were enrolled as controls. Besides, none of the participants were diagnosed with the following diseases: cancer, acute inflammation, hematological system disorders, congenital heart disease, history of previous myocardial infarction (MI), hepatic failure, or other severe disorders. The basic information and clinical characteristics of participants were shown in Table 1. Our study was authorized by the Medical Ethics Committee of Zhongnan Hospital of Wuhan University.

Table 1
Clinical characteristics of subjects in validation study

| Characteristic          | Controls | CAD patients | P value |
|-------------------------|----------|--------------|---------|
| **Demographics**        |          |              |         |
| Male/Female             | 17/13    | 22/8         | 0.2789  |
| Age (year)              | 55.27 ± 9.03 | 59.80 ± 9.26 | 0.0598  |
| **Risk factors**        |          |              |         |
| History of HP (yes/no)  | 9/21     | 20/10        | 0.0092  |
| History of DM (yes/no)  | 1/29     | 8/22         | 0.0257  |
| **Clinical parameters** |          |              |         |
| TC (mmol/L)             | 4.25 ± 0.72 | 4.53 ± 1.45  | 0.3429  |
| TG (mmol/L)             | 1.14 ± 0.39 | 1.89 ± 1.43  | <0.001  |
| LDL-C (mmol/L)          | 2.60 ± 0.60 | 2.80 ± 1.08  | 0.3701  |
| HDL-C (mmol/L)          | 1.41 ± 0.34 | 1.30 ± 0.47  | 0.2964  |
| FPG (mmol/L)            | 5.48 (5.03, 5.73) | 5.69 (5.18, 6.90) | 0.0740  |
| WBC (× 10^9)            | 5.84 ± 1.33 | 6.33 ± 1.77  | 0.2290  |
| Monocyte (× 10^9)       | 0.43 ± 0.11 | 0.58 ± 0.21  | <0.001  |
| Neutrophil (× 10^9)     | 3.31 ± 1.03 | 3.97 ± 1.28  | 0.0315  |
| Lymphocyte (× 10^9)     | 1.93 ± 0.51 | 1.60 ± 0.61  | 0.0250  |
| LMR (ratio)             | 4.68 ± 1.17 | 2.98 ± 1.21  | <0.001  |
| NMR (ratio)             | 7.70 (6.13, 8.85) | 6.48 (5.53, 8.90) | 0.1973  |
| NLR (ratio)             | 1.68 (1.30, 2.05) | 2.58 (1.94, 3.20) | <0.001  |

Data were showed as mean ± SD, median (25 percentiles, 75 percentiles).

HP, hypertension; DM, diabetes mellitus; TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; FPG, fasting plasma glucose; WBC, white blood cell; LMR, lymphocyte to monocyte ratio; NMR, neutrophil to monocyte ratio; NLR, neutrophil to lymphocyte ratio.

Quantitative Real-time PCR

RNA was isolated from PBLs of 30 CAD patients and 30 controls by TRIZOL reagent (Life Technologies, USA) with the guidance of instruction. To assess the concentration and purity of RNA, NanoDrop 2000C (Thermo Fisher Scientific, USA) was applied. About 1 microgram RNA of each sample was used for reverse transcription into complementary DNA (cDNA) through the PrimeScript™ RT reagent kit with gDNA Remover (Takara, Japan). The qPCR was carried out using SYBR Green I UltraSYBR Mixture (CWBIO, China) on Bio-Rad CFX96 (Bio-Rad Laboratories, USA). We took glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as endogenous reference gene to normalize the expression level among multiple samples. The specific sequences of each pair of primers were available in Additional file 2:
Table S1. All experiments were implemented in duplicate to intensify the credibility. Relative gene expression status was calculated by $2^{-\Delta Cq}$ method, in which $\Delta Cq$ stands for the difference between the mean $Cq$ (quantification cycle) of a target gene and the endogenous reference gene (GAPDH).

**Statistical analysis**

Mean ± standard deviation (SD) was utilized to describe the basic information and clinical characteristics that were normal distributed continuous variables. Abnormal distributed continuous variables were depicted as median and inter-quartile range. Categorical variables were exhibited by frequencies. We applied student’s t test or Mann-Whitney U tests to compare the difference between 2 groups based on the distribution type. Chi-square test or Fisher’s exact test was performed for comparison of categorical variables between groups. Pearson or Spearman test was used for correlation analysis. We utilized multivariate stepwise linear regression to eliminate interference factors in regression analysis. All statistical analyses of this research were conducted through SPSS version 25.0 (SPSS Inc., USA) and GraphPad Prism 8.0 (GraphPad Inc., USA). Statistically significant threshold of two-sided $P$ value was set at 0.05.

**Results**

**General characteristics of DEGs, DMCs, DMGs and DEMGs**

A total of 3351 DEGs were identified, among which 1863 genes were up-regulated and 1488 genes were down-regulated in CAD patients’ PBLs compared with controls. Another microarray dataset from GEO (GSE107143) was used to explore DMCs among approximate 450,000 CpGs in 8 CAD patients and 8 controls. In aggregate, 7694 DMCs were confirmed and 3362 of DMCs were hypermethylated and the other 4332 DMCs were hypomethylated according to the $\log_2 FC$ of delta of beta value. The distribution of DMCs on chromosomes was exhibited in Fig. 1. Interestingly, none of DMCs were found on short arms of chromosome 13, 14, 15, 21 and 22. Meanwhile, it was observed that DMCs in regions around centromeres were relatively sparse compared to other chromosome regions, which indicates that there might to be correlation between chromosome structure and gene methylation status.

To probe into the potential effect of the whole intragenic regions’ methylation status on gene function, we considered genes with one or more DMRs that differentially methylated in the same direction as DMGs. About 2413 hypermethylated genes and 2952 hypomethylated genes were
classified based on DMRs. Subsequently, 135 genes were identified as up-expressed and hypermethylated (up-hyper genes), 212 genes were confirmed as up-expressed and hypomethylated (up-hypo genes), 100 genes were taken as down-expressed and hypermethylated (down-hyper genes), 88 genes were considered as down-expressed and hypomethylated (down-hypo genes) by overlapping DEGs and DMGs (Fig. 2a).

In addition, to further explore whether the integration analysis of expression and methylation data was able to identify potential functional genes in CAD efficiently, another expression microarray GSE71226 was analyzed. As displayed in Additional file 3: Fig. S2, there were 281 (2.4%) overlapped up-regulated genes and 160 (1.4%) overlapped down-regulated genes in overlaps of GSE42148 and GSE71226 expression arrays. By contrast, combination of expression and methylation arrays identified more overlapped DEGs with 347 (5.1%) up-regulated and 188 (2.8%) down-regulated, which demonstrated a higher sensitivity (Fig. 2a).

In total, 535 differentially expressed and methylated genes were screened out as DEMGs. It was worth noting that up-hyper genes and down-hypo genes occupied virtually half of DEMGs, which indicated the multidirectional regulation of methylation on gene function that worth of further study. Heatmaps were formed according to hierarchical clustering of gene expressions or methylations levels to exhibit the top 50 ranked DEMGs by log²FC, respectively (Fig. 2b, c).

**Distributions Of DMCs In Intragenic Regions**

According to the analysis result of DMCs distributions, it showed inhomogeneous distributions of DMCs in 6 intragenic regions no matter for DMGs or DEMGs. As Fig. 3a and Fig. 3b showed, DMCs located in TSS1500 and body of both DMGs and DEMGs, accounted for over 50% of the total DMCs numbers. On the contrast, there were only less than 3% DMCs distributed in 3’UTR. In consideration of the linear lengths of TSS1500 and body are much longer than TSS200 and 5’UTR, it is more reasonable to take TSS200 and 5’UTR as the high enrichment areas of DMCs. These results above indicated the significant correlation of TSS200 and 5’UTR methylation status and gene expression. Besides, the similar distribution mode can be found in 4 kinds of DEMGs (Fig. 3c). It can be observed that DMCs in 6 intragenic regions were mostly possessed by up-hypo genes, which manifested up-
hypo genes as major roles in epigenetic regulation of CAD.

To demonstrate the relevance among intragenic regions, UpSet plots were drawn to describe the methylation status of a certain DMG with one or more DMRs. Over 70% of both hypermethylated genes and hypomethylated genes were single region-specific DMGs in TSS1500, TSS200, 5’UTR and body (Fig. 3d, e). While, DMGs with multiple DMRs were mainly occupied by 5’UTR and 1stExon, TSS1500 and TSS200, TSS200 and 5’UTR. Even more noteworthy is that approximately 6% DMGs had 3 or more differentially methylated regions, which represented a general differential methylation status of a certain gene in CAD patients compared to controls.

**GO Functional And KEGG Pathway Enrichment Analysis Of DEMGs**

We performed GO functional and KEGG pathway enrichment analysis on up-hyper, up-hypo, down-hyper, down-hypo genes separately to explore the inner connection of DEMGs. The top 5 GO enrichment terms were illustrated in Table 2, from which we could find DEMGs enriched in numerous processes. Up-hyper genes were basically enriched in the biological process and 2 terms were associated with actin cytoskeleton reorganization. Four fifths of terms enriched on up-hypo genes were related to organelle membrane or granule membrane. It is notable that the rest 1 term of up-hypo genes was neutrophil activation which enriched most genes among the top 5 terms. AS for down-hyper genes, GO terms were majorly centered on DNA-directed RNA polymerase activity, which indicate the potential connection between DNA methylation and mRNA expression. Besides, 2 terms of down-hypo genes were involved in regulation of calcium ion transportation.

| Category          | Terms | ID            | Description                          | Gene count | %   | P value    | Genes                  |
|-------------------|-------|---------------|--------------------------------------|------------|-----|------------|------------------------|
| Up-hyper genes    | BP    | GO:0034446    | Substrate adhesion-dependent cell spreading | 6          | 5.77| 2.02E-05   | ABL1, CDC42, FER, FN1, MICALL2, TRIOBP |
|                   | BP    | GO:2000251    | Positive regulation of actin cytoskeleton reorganization | 3          | 2.88| 1.52E-04   | ABL1, BAIAPI2L1, CDC42 |
|                   | BP    | GO:0042749    | Regulation of circadian sleep/wake cycle | 3          | 2.88| 2.08E-04   | CHRN8, NR1D1, PER3      |
|                   | BP    | GO:0031532    | Actin cytoskeleton reorganization      | 5          | 4.81| 2.52E-04   | ABL1, BAIAPI2L1, CDC42, FER |

Table 2
List of top enriched GO terms of 4 DEMGs groups
| BP   | GO:2000637 | Positive regulation of gene silencing by miRNA | 3 | 2.88 | 2.74E-04 | DDX5, STA13, TRIM71 |
|------|-------------|-----------------------------------------------|---|------|----------|-------------------|

**Up-hypo genes**

| CC   | GO:0016323 | Basolateral plasma membrane                  | 11 | 6.01 | 6.06E-06 | ABC1, AO2P9, ATP6V1B1, B4GALT1, CD34, EZR, FLAT2, KCNO1, MAP7, SLC19A1, SLC2A3 |
|------|-------------|-----------------------------------------------|---|------|----------|-------------------|

| CC   | GO:0035579 | Specific granule membrane                     | 7  | 3.83 | 2.22E-05 | CD59, MMP25, MS4A3, PLAUR, PLD1, PTPRJ, VAMP1 |
|------|-------------|-----------------------------------------------|---|------|----------|-------------------|

| CC   | GO:0030667 | Secretory granule membrane                    | 12 | 6.56 | 2.33E-05 | B4GALT1, CD59, CEACAM6, FLOT2, ICA1, MMP25, MS4A3, PLAUR, PLD1, PTPRJ, SLC11A1, VAMP1 |
|------|-------------|-----------------------------------------------|---|------|----------|-------------------|

| CC   | GO:0033116 | Endoplasmic reticulum Golgi intermediate compartmemt membrane | 6  | 3.28 | 5.11E-05 | AREG, CD59, CSNK1D, ERGIC1, MPPE1, NAT8 |
|------|-------------|---------------------------------------------------------------|---|------|----------|-------------------|

| BP   | GO:0042119 | Neutrophil activation                                       | 15 | 8.62 | 6.84E-05 | B4GALT1, CAP1, CD59, CEACAM6, CUX1, IMPDH1, MMP25, MMP9, MPO, MS4A3, OLF4, PLAUR, PLD1, PTPRJ, SLC11A1 |
|------|-------------|---------------------------------------------------------------|---|------|----------|-------------------|

**Down-hypo genes**

| MF   | GO:0003899 | DNA-directed 5'-3' RNA polymerase activity                   | 3  | 3.53 | 9.99E-04 | CD3EAP, POLR3A, ZNRD1 |
|------|-------------|---------------------------------------------------------------|---|------|----------|-------------------|

| CC   | GO:0030008 | TRAPP complex                                                | 2  | 2.30 | 1.23E-03 | TRAPPC4, TRAPPC5 |
|------|-------------|---------------------------------------------------------------|---|------|----------|-------------------|

| CC   | GO:0055029 | Nuclear DNA-directed RNA polymerase complex                   | 4  | 4.60 | 1.29E-03 | CD3EAP, POLR3A, RPRD1A, ZNRD1 |
|------|-------------|---------------------------------------------------------------|---|------|----------|-------------------|

| MF   | GO:0034062 | 5'-3' RNA polymerase activity                                 | 3  | 3.53 | 1.31E-03 | CD3EAP, POLR3A, ZNRD1 |
|------|-------------|---------------------------------------------------------------|---|------|----------|-------------------|

| MF   | GO:0097747 | RNA polymerase activity                                       | 3  | 3.53 | 1.31E-03 | CD3EAP, POLR3A, ZNRD1 |
|------|-------------|---------------------------------------------------------------|---|------|----------|-------------------|

**Down-hypo genes**

| BP   | GO:0034644 | Cellular response to UV                                      | 4  | 5.80 | 2.40E-04 | CRIP1, DHX36, TREX1, TRIAP1, S100A6 |
|------|-------------|---------------------------------------------------------------|---|------|----------|-------------------|

| BP   | GO:0002244 | Hematopoiesis                                                | 5  | 7.25 | 8.31E-04 | C12orf29, GPN2, PCDH23, PTCH1, RBP1C3, RBP1C4 |
|------|-------------|---------------------------------------------------------------|---|------|----------|-------------------|
| BP | GO:0002244 | Hematopoietic progenitor cell differentiation | 7.25 | 3.71E-04 | C12orf29, DHX36, TCF12, TREX1, ZBTB24 |
| BP | GO:0051281 | Positive regulation of release of sequestered calcium ion into cytosol | 3 | 4.35 | 4.33E-04 | F2RL3, P2RY6, TRPC1 |
| BP | GO:0045668 | Negative regulation of osteoblast differentiation | 3 | 4.35 | 8.86E-04 | HOXA2, ID3, LIMD1 |
| BP | GO:0010524 | Positive regulation of calcium ion transport into cytosol | 3 | 4.35 | 1.05E-03 | F2RL3, P2RY6, TRPC1 |

Table 3 exhibited top KEGG pathways of 4 kinds DEMGs. Enrichment analysis suggested up-hyper genes were significantly enriched in VEGF signaling pathway and adipocytokine signaling pathway that might link with blood lipids. Up-hypo genes mainly enriched in autophagy, vitamin digestion and absorption, and PI3K-Akt signaling pathway. There were less KEGG pathways enriched in down-hyper and down-hypo genes by comparison with up-regulated DEMGs. Only 2 pathways RNA polymerase and Fanconi anemia pathway, were identified in down-hyper genes. Down-hypo genes were associated with other types of O-glycan biosynthesis, cytosolic DNA-sensing pathway, mRNA surveillance pathway, and non-homologous end-joining.
| Category          | ID       | Description                              | Gene count | %     | P value  | Genes                                      |
|-------------------|----------|------------------------------------------|------------|-------|----------|--------------------------------------------|
| **Up-hyper genes**|          |                                          |            |       |          |                                            |
| hsa04370         | VEGF signaling pathway | 5          | 9.80      | 3.44E-05 | AKT2, CDC42, KDR, PPP3CA, PTGS2 |
| hsa05206         | MicroRNAs in cancer       | 8          | 15.69     | 7.21E-04 | ABL1, IRS2, MARCKS, PTGS2, RPS6KA5, SOX4, STAT3, TRIM71 |
| hsa04722         | Neurotrophin signaling pathway | 5          | 9.80      | 9.38E-04 | ABL1, AKT2, CDC42, IRAK3, RPS6KA5 |
| hsa04920         | Adipocytokine signaling pathway | 4          | 7.84      | 9.57E-04 | AKT2, IRS2, RXRG, STAT3 |
| hsa05165         | Human papillomavirus infection | 8          | 15.69     | 1.08E-03 | AKT2, CDC42, FN1, ITGB4, MAML2, MAML3, PTGS2, THBS4 |
| **Up-hypo genes**|          |                                          |            |       |          |                                            |
| hsa04140         | Autophagy - animal          | 7          | 7.87      | 8.25E-04 | ATG16L2, CAMKK2, CFLAR, KRAS, PPP2CA, PTEN, TP53INP2 |
| hsa04977         | Vitamin digestion and absorption | 3          | 3.37      | 2.32E-03 | ABC1C1, SLC19A1, SLC23A1 |
| hsa04710         | Circadian rhythm            | 3          | 3.37      | 4.87E-03 | BHLHE40, CSNK1D, PER1 |
| hsa04151         | PI3K-AKT signaling pathway | 10         | 11.24     | 6.00E-03 | AREG, CSF3R, IFNAR2, KIT, KRAS, MYB, PIK3R6, PPP2CA, PTEN, SGK1 |
| hsa05221         | Acute myeloid leukemia       | 4          | 4.49      | 6.59E-03 | KIT, KRAS, MPO, RUNX1 |
| **Down-hyper genes** |          |                                          |            |       |          |                                            |
| hsa03020         | RNA polymerase              | 2          | 7.41      | 4.87E-03 | POLR3A, ZNRD1 |
| hsa03460         | Fanconi anemia pathway       | 2          | 7.41      | 1.43E-02 | FANCF, FANCL |
| **Down-hypo genes** |          |                                          |            |       |          |                                            |
| hsa00514         | Other types of O-glycan biosynthesis | 2          | 6.90      | 1.21E-02 | GALNT3, LFNG |
| hsa04623         | Cytosolic DNA-sensing pathway | 2          | 6.90      | 2.19E-02 | AIM2, TREX1 |
| hsa03015         | mRNA surveillance pathway   | 2          | 6.90      | 4.31E-02 | PPP2R2B, RNGT1 |
| hsa03450         | Non-homologous end-joining  | 1          | 3.45      | 4.65E-02 | RAD50 |

**PPI Network Establishment, Module Analysis And Hub Genes Identification**

To excavate the interaction among DEMGs, PPI networks based on STRING were visualized by Cytoscape for 4 kinds of DEMGs respectively. The radius of each gene circle in PPI network was positively associated with absolute value of log₂FC of mRNA expression between CAD patients and controls. Analogously, the color depth of each gene circle represents the methylation status of genes.
in PPI network. Put it in a concrete way, the darker the color, the greater the difference of methylation levels between 2 study populations. Module analysis was performed to simplify the PPI network and focus on certain modules with stronger interactions. Subsequently, hub genes were filtered by 12 algorithms based on bioinformatic analysis.

As displayed in Fig. 4a and Fig. 4b, top 10 hub genes of up-hyper genes are FN1, STAT3, CDC42, DDX5, ABL1, PTGS2, PCKS2, PNISR, XRN2 and SF1. PPI network, top 3 modules and top 10 up-hypo hub genes were shown in Fig. 4c and Fig. 4d. More precisely, top 10 hub genes of up-hypo genes including PTEN, KRAS, MMP9, MAP1LC3A, ITCH, TGOLN2, CD34, KIT, WDFY4 and SPTBN1. The same module analysis and hub gene screening were performed on down-hyper genes, confirming the top 10 hub genes were POLR3A, HIST1H4B, CTTNBP2, EED, CETN3, TUBE1, FHL2, GRID2, GMNN and MRPL39 (Fig. 4e, f). While the top 10 hub genes based on interaction information from PPI network of down-hypo genes were UBR1, TREX1, CDKN1C, UBE2T, ID3, DHX36, LFNG, LIMD1, EPHB3 and AIM2 (Fig. 4g, h).

**GO Functional Enrichment Analysis Of Hub Genes**

For purpose of illustration the functional interrelation of hub genes, GO enrichment analysis was conducted in top 10 hub genes of 4 DEMGs groups (Fig. 5). Up-hyper hub genes were majorly enriched in terms of acute-phase response and positive regulation of posttranscription. Regulation of synaptic function and membrane biogenesis were the main terms enriched in up-hypo genes. Intriguingly, down-hyper genes were observed to be associated with regulation of histone H3-K27 methylation and participated in regulation of postsynaptic that was similar with up-hypo genes. Terms enriched in down-hypo genes were mostly related to response to interferons and urogenital system development.

**Clinical Characteristics Of Subjects In Validation Study**

The clinical parameters of CAD patients and controls were summarized in Table 1. Groups of participants were matched in gender and age structure. More CAD patients suffered from hypertension (HP) \((P = 0.009)\) and diabetes mellitus (DM) \((P = 0.025)\) compared with controls. Among the serum lipid parameters, no conspicuous differences were observed in total cholesterol (TC), low
density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C). While, the level of triglyceride (TG) was much higher in CAD patients ($P < 0.001$). Leucocyte differential count revealed significant increase of monocytes ($P < 0.001$) and neutrophils ($P = 0.031$) but prominent decrease of lymphocytes ($P = 0.025$) in CAD patients. Parameters based on leucocyte differential counts such as the lymphocyte to monocyte ratio (LMR) ($P < 0.001$) was decreased while the neutrophil to lymphocyte ratio (NLR) ($P < 0.001$) was increased in CAD patients.

**Hub Genes Expression In Validation Study**

In order to validate the significance of hub genes identified based on bioinformatic analysis, the mRNA expression levels of top 1 hub genes from 4 DEMGs groups were detected by qPCR. In accord with the bioinformatic results, FN1 from up-hyper genes and PTEN belonged to up-hypo genes were remarkably upregulated in CAD patients when compared with controls (Fig. 6a, b). The mRNA expression level of POLR3A, the top 1 hub gene of down-hyper genes, was conspicuously decreased in patients with CAD, which was also consistent with the bioinformatic results above (Fig. 6c). Nevertheless, the foremost hub gene UBR1 from down-hypo genes was not differentially expressed between CAD patients and controls (Fig. 6d).

In consideration of these hub genes were screened from DEMGs, we speculated the significant expression differences of FN1, PTEN and POLR3A were in all probability correlated with the aberrant DNA methylation status in CAD patients, which could be a more stable biomarker compared with mRNA expression.

**Correlation Between Hub Genes Expressions And Clinical Characteristics**

Correlation analysis and multivariate stepwise linear regression analysis were performed to investigate the underlying connection between clinical characteristics of all enrolled subjects and expression levels of top 1 hub genes. As displayed in Table 4, both FN1 ($r = 0.268$, $P = 0.039$) and PTEN ($r = 0.326$, $P = 0.011$) were identified to be positively correlated with monocyte counts. LMR was observed to be negatively related with FN1 ($r = -0.255$, $P = 0.049$) and PTEN ($r = -0.315$, $P = 0.014$), and positively correlated with POLR3A ($r = 0.288$, $P = 0.026$). Besides, PTEN was reversely associated with NMR ($r = -0.311$, $P = 0.016$) and the expression of POLR3A was decreased with aging ($r = -0.320$,
P = 0.013). In addition, although the expression of UBR1 was not confirmed to be different between CAD patients and controls, a prominent reverse correlation was verified between UBR1 and TG when involved all subjects (r = -0.312, P = 0.012).

Table 4
Correlation analysis and multivariate stepwise linear regression analysis of gene expression with clinical parameters of all participants

| Characteristics | FN1 (n = 60) | PTEN (n = 60) | POLR3A (n = 60) | UBR1 (n = 60) |
|-----------------|-------------|---------------|-----------------|--------------|
|                 | r           | p value       | β              | p value      | r           | p value       | β              | p value      | r           | p value       | β              | p value      |
| Age             | 0.221       | 0.090         | 0.134          | 0.308        | -0.320       | 0.013         | -0.320         | 0.013        | -0.22        | 0.087         |                   |             |
| Gender          | -0.114      | 0.385         | -0.087         | 0.508        | 0.030        | 0.817         | -0.14          | 0.285        | -0.143       | 0.276         |                   |             |
| History of HP   | 0.083       | 0.530         | 0.141          | 0.284        | -0.212       | 0.093         | -0.140         | 0.285        | -0.143       | 0.276         |                   |             |
| History of DM   | 0.151       | 0.250         | 0.019          | 0.884        | 0.050        | 0.707         | -0.140         | 0.276        | -0.143       | 0.276         |                   |             |
| TC              | 0.092       | 0.494         | 0.037          | 0.784        | 0.124        | 0.358         | 0.164          | 0.224        | -0.312       | 0.012         | -0.312         | 0.012         |
| TG              | 0.192       | 0.153         | 0.123          | 0.361        | -0.07        | 0.598         | -0.312         | 0.012        | -0.312       | 0.012         | -0.312         | 0.012         |
| LDL-C           | 0.052       | 0.701         | 0.014          | 0.918        | 0.145        | 0.283         | 0.132          | 0.327        | -0.312       | 0.012         | -0.312         | 0.012         |
| HDL-C           | -0.129      | 0.341         | -0.15          | 0.267        | 0.042        | 0.759         | 0.194          | 0.148        | -0.312       | 0.012         | -0.312         | 0.012         |
| WBC             | -0.086      | 0.512         | -0.06          | 0.619        | -0.02        | 0.871         | -0.03          | 0.818        | -0.312       | 0.012         | -0.312         | 0.012         |
| Monocyte        | 0.268       | 0.039         | 0.268          | 0.039        | 0.326        | 0.011         | 0.326          | 0.011        | -0.083       | 0.497         | 0.022          | 0.866         |
| Neutrophil      | 0.004       | 0.974         | 0.070          | 0.593        | -0.10        | 0.439         | -0.10          | 0.440        | -0.312       | 0.012         | -0.312         | 0.012         |
| Lymphocyte      | 0.144       | 0.271         | 0.089          | 0.500        | 0.207        | 0.113         | 0.113          | 0.390        | -0.312       | 0.012         | -0.312         | 0.012         |
| LMR             | -0.255      | 0.049         | -0.210         | 0.055        | -0.315       | 0.014         | -0.205         | 0.066        | 0.288        | 0.026         | 0.104          | 0.128         |
| NMR             | -0.125      | 0.342         | -0.311         | 0.016        | -0.231       | 0.069         | 0.046          | 0.730        | -0.13        | 0.301         | 0.137          | 0.568         |
| NLR             | 0.230       | 0.077         | 0.025          | 0.847        | -0.18        | 0.157         | 0.012          | 0.361        | -0.312       | 0.012         | -0.312         | 0.012         |

After adjustment of LMR by multivariate stepwise linear regression, the positive correlation of FN1 with monocyte counts (β = 0.268, P = 0.039) still existed. When eliminated the interference of LMR and NMR, PTEN was still associated with monocyte amount (β = 0.326, P = 0.011). While, POLR3A remained to be related with age (β = -0.320, P = 0.013) after adjusting LMR.

Discussion
Identify epigenetic pattern and certain biomarkers from PBLs would be conducive to the diagnosis, therapy and monitor of CAD in non-invasive approach. In this study, we filtrated genes that were both discrepantly expressed and methylated in CAD patients compared with controls. Pathways enriched by these genes were demonstrated and hub genes were screened out based on PPI network. To verify
the results of data analysis, top hub genes were experimentally confirmed through qPCR in CAD patients and controls. Furthermore, we investigated methylation patterns based on separate gene regions and gave evidence of the most vulnerable region to methylation in CAD. The differential expressions of hub genes filtered from DEMGs were with great possibility to be associated with altered DNA methylation status, which shed light on the underlying regulation mechanism of DNA methylation in CAD and helped identification of the stable novel DNA methylation biomarkers.

As the chromosome distribution map exhibited, differentially methylated CpGs covered almost every regions of each chromosome. This can be regarded as the universality of methylated regulation in the pathogenesis of CAD [24]. It is interesting to note that DMCs distributed in regions near centromeres were relatively fewer than other regions. The phenomenon might be partly attribute to the supercoiling structure and hyper-reiterated DNA sequence around the centromeres [25].

Numerous published studies took promoters as key differentially methylated regions in CAD, while other intragenic regions were less concerned [26, 27]. Recently, a few studies have demonstrated methylation sites in gene body or TSS1500 were also essential to the pathogenesis of CAD [28]. Our research confirmed gene body and TSS1500 possessed almost half of DMCs, no matter in DMGs or DEMGs. Nevertheless, TSS200 and 5’UTR were the most enriched intragenic areas of DMCs when took the linear length into consideration. A portion of hypermethylation and hypomethylation genes showed discrepant methylation status in both 5’UTR and 1stExon, or TSS1500 and TSS200, or TSS200 and 5’UTR. In view of the adjacent spatial positions of the 3 pairs regions, a rational inference could be raised that methylation status of CpGs were with obvious spatiality and regionality. Besides, we divided DEMGs into 4 groups and demonstrated up-hypo genes as the major part functioning in the progress of CAD. When compared with simplex analysis that combining multiple expression arrays, integration of expression and methylation arrays showed higher overlapping ratio, which suggested the high sensitivity and yielding of our research in identification underlying functional genes regulated by DNA methylation.

KEGG pathway enrichment analysis suggested up-hyper genes mainly enriched in adipocytokine signaling pathway and VEGF signaling pathway. It was consistent with previous studies that increased
expression of the adipocytokine omentin was detected in the epicardial adipose tissue of CAD patients and unbalance of isoforms of VEGF was associated with the complexity and severity of CAD [29, 30]. Up-hypo genes primarily enriched in neutrophil activation and it has been confirmed by several researches that increased neutrophil counts was connected with the severity of CAD [31]. Intriguingly, hub genes belonged to down-hyper genes were directly correlated with regulation of histone H3-K27 methylation according to GO enrichment analysis, which indicated underlying association between DNA methylation and histone methylation. Regulation of calcium ion transport into cytosol was the term enriched by down-hypo genes and has been proved to affect the progress of CAD through coronary smooth muscle [32].

In view of the small sample size of datasets obtained from GEO database and accumulative deviation from bioinformatics analysis, we performed laboratorial verification with relatively larger sample size for top 1 hub genes of each DEMGs group. The results of qPCR suggested accordant expression levels of FN1, PTEN and POLR3A in comparison with bioinformatics analysis results. To further investigate into the mechanism of FN1, PTEN and POLR3A in the pathogenesis of CAD, correlation analysis and multivariate stepwise linear regression analysis were performed. FN1 was positively correlated with monocyte counts. Positive correlation was also observed in PTEN with monocyte amount. POLR3A was negatively related with age. These results indicated that FN1 and PTEN might function in the systemic infection since the monocytosis was the acknowledged systemic infection index.

Inflammatory cytokines activated TGF-β signaling pathway, which promoted the expression of FN1 in human endothelial cells [33]. Fibronectin, encoded by FN1, was enriched in vascular subendothelial basement membrane during the early process of atherosclerotic plaque formation and aggravated the monocytes recruitment [34]. The significant up-regulation of FN1 was positively related with monocyte amount in CAD patients confirmed the previous explored regulation pathways. The vascular endothelial cells injury caused by chronic inflammatory in atherosclerosis accelerated the atherosclerotic plaque formation. A series of microRNAs could bind to the 3'UTR of PTEN, altered the proliferation of vascular endothelial cells through PI3K-Akt pathway and influenced the procession of CAD [35]. Previous reports suggested PTEN was up-regulated in peripheral blood mononuclear cells of
CAD patients, which was consistent with our founding in PBLs and confirmed the reliability of our research [36]. In addition to the involvement of microRNAs in the regulation of PTEN, we conjectured DNA methylation might also participated in the regulation network. POLR3A mainly triggered leukodystrophy [37]. And currently, no study was carried out to research the function of POLR3A in CAD or atherosclerosis. The aberrant expression and methylation of POLR3A may serve as novel potential biomarkers of CAD.

Conclusions

In summary, our study consolidated both mRNA expression and DNA methylation microarrays of PBLs in CAD into bioinformatics analysis and executed experimental validation for the first time. Methylation patterns of CAD were confirmed based on the distribution of DMCs in chromosomes and intragenic regions. FN1, PTEN and POLR3A were screened as top hub genes through bioinformatics analysis and were confirmed with subsequent experimental verification in a Chinese case-control study. Further molecular and clinical experiments with larger sample size are needed to illuminate the underlying mechanism of the differential expression and methylation of FN1, PTEN and POLR3A and to explore functions of DNA methylation on these genes in pathogenesis of CAD.

List Of Abbreviations

CAD, coronary artery disease; PBL, peripheral blood leukocyte; GEO, Gene Expression Omnibus; DEG, Differentially expressed gene; DMG, differentially methylated gene; DMC, differentially methylated CpG; DEMG, differentially expressed-methylated gene; DMR, differentially methylated region; FN1, fibronectin 1; PTEN, phosphatase and tensin homolog; POLR3A, RNA polymerase III subunit A; CAG, coronary arteriography; RCT, reverse cholesterol transport; q-PCR, quantitative real-time PCR; TSS, transcriptional start site; BP, biological process; CC, cellular component; MF, molecular function; MI, myocardial infarction; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; Cq, quantification cycle; HP, hypertension; DM, diabetes mellitus; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglyceride; LMR, lymphocyte to monocyte ratio; NLR, neutrophil to lymphocyte ratio.

Declarations

Ethics approval and consent to participate
Our study was authorized by the Medical Ethics Committee of Zhongnan Hospital of Wuhan University and consent was obtained from all participants.

**Consent for publication**
Not applicable

**Availability of data and materials**
Gene Expression omnibus (GEO) was the source of the primary data. The gene expression data can be found at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE42148 and https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71226. DNA methylation data can be downloaded at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107143.

**Competing interests**
The authors declare that they have no competing interests.

**Funding**
This work was supported by grants of the National Natural Science Foundation of China (grant nos. 81871722).

**Authors’ contributions**
FZ conceived and designed the workflow. XKZ performed the experiments, analyzed the data and wrote the paper. YX collected the samples. DDH analyzed the data and did figure creation. BL, CW and JL revised the manuscript. All authors approved the final manuscript.

**Acknowledgements**
Not applicable

**Authors’ information**
1 Center for Gene Diagnosis, and Clinical Lab, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan 430071, China

**References**
1. Wood D, Eisele JL. A global coalition for the fight against heart disease and stroke. Lancet. 2017;390(10108):2130-1.
2. Moran A, Zhao D, Gu D, Coxson P, Chen CS, Cheng J, et al. The future impact of
population growth and aging on coronary heart disease in China: projections from the Coronary Heart Disease Policy Model-China. BMC public health. 2008;8:394.

3. Gaziano TA, Suhrcke M, Brouwer E, Levin C, Nikolic I, Nugent R. Costs and Cost-Effectiveness of Interventions and Policies to Prevent and Treat Cardiovascular and Respiratory Diseases. In: Prabhakaran D, Anand S, Gaziano TA, Mbanya JC, Wu Y, et al., editors. Cardiovascular, Respiratory, and Related Disorders. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017. Chapter 19.

4. De Marco E, Vacchiano G, Frati P, La Russa R, Santurro A, Scopetti M, et al. Evolution of post-mortem coronary imaging: from selective coronary arteriography to post-mortem CT-angiography and beyond. La Radiologia medica. 2018;123(5):351-8.

5. Rusnak J, Fastner C, Behnes M, Mashayekhi K, Borggrefe M, Akin I. Biomarkers in Stable Coronary Artery Disease. Current pharmaceutical biotechnology. 2017;18(6):456-71.

6. Duan L, Liu C, Hu J, Liu Y, Wang J, Chen G, et al. Epigenetic mechanisms in coronary artery disease: The current state and prospects. Trends in cardiovascular medicine. 2018;28(5):311-9.

7. Xu S, Kamato D, Little PJ, Nakagawa S, Pelisek J, Jin ZG. Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics. Pharmacology & therapeutics. 2019;196:15-43.

8. Bashore AC, Liu M, Key CC, Boudyguina E, Wang X, Carroll CM, et al. Targeted Deletion of Hepatocyte Abca1 Increases Plasma HDL (High-Density Lipoprotein) Reverse Cholesterol Transport via the LDL (Low-Density Lipoprotein) Receptor. Arteriosclerosis, thrombosis, and vascular biology. 2019;39(9):1747-61.

9. Peng P, Wang L, Yang X, Huang X, Ba Y, Chen X, et al. A preliminary study of the
relationship between promoter methylation of the ABCG1, GALNT2 and HMGCR genes and coronary heart disease. PloS one. 2014;9(8):e102265.

10. Ghaznavi H, Mahmoodi K, Soltanpour MS. A preliminary study of the association between the ABCA1 gene promoter DNA methylation and coronary artery disease risk. Molecular biology research communications. 2018;7(2):59-65.

11. Szijarto IA, Marko L, Filipovic MR, Miljkovic JL, Tabeling C, Tsvetkov D, et al. Cystathionine gamma-Lyase-Produced Hydrogen Sulfide Controls Endothelial NO Bioavailability and Blood Pressure. Hypertension. 2018;71(6):1210-7.

12. Li JJ, Li Q, Du HP, Wang YL, You SJ, Wang F, et al. Homocysteine Triggers Inflammatory Responses in Macrophages through Inhibiting CSE-H2S Signaling via DNA Hypermethylation of CSE Promoter. International journal of molecular sciences. 2015;16(6):12560-77.

13. Giannakopoulou E, Konstantinou F, Ragia G, Tavridou A, Karaglani M, Chatzaki E, et al. Epigenetics-by-Sex Interaction for Coronary Artery Disease Risk Conferred by the Cystathionine gamma-Lyase Gene Promoter Methylation. Omics: a journal of integrative biology. 2017;21(12):741-8.

14. Yamada Y, Horibe H, Oguri M, Sakuma J, Takeuchi I, Yasukochi Y, et al. Identification of novel hyper- or hypomethylated CpG sites and genes associated with atherosclerotic plaque using an epigenome-wide association study. International journal of molecular medicine. 2018;41(5):2724-32.

15. Oudejans C, Poutsma A, Michel O, Mulders J, Visser A, Dijk M, et al. Genome-Wide Identification of Epigenetic Hotspots Potentially Related to Cardiovascular Risk in Adult Women after a Complicated Pregnancy. PloS one. 2016;11(2):e0148313.

16. Nakatochi M, Ichihara S, Yamamoto K, Naruse K, Yokota S, Asano H, et al. Epigenome-wide association of myocardial infarction with DNA methylation sites at loci related
to cardiovascular disease. Clinical epigenetics. 2017;9:54.

17. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic acids research. 2015;43(7):e47.

18. Conway JR, Lex A, Gehlenborg N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics. 2017;33(18):2938-40.

19. Zhaodong H, Dekang L, Ying G, Jisen S, Dolf W, Guangchuang Y, et al. RIdogram: drawing SVG graphics to visualize and map genome-wide data on idiograms. https://cran.r-project.org/web/packages/RIdogram. Assessed 06 October 2019.

20. Midori A, Jennifer I, Amelia I, Jane L, Michael A, Russell C, et al. The Gene Ontology (GO) project in 2006. Nucleic acids research. 2006;34:322-6.

21. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids research. 2000;28(1):27-30.

22. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research. 2003;13(11):2498-504.

23. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC systems biology. 2014;Suppl 4:S11.

24. Deng Q, Huang W, Peng C, Gao J, Li Z, Qiu X, et al. Genomic 5-mC contents in peripheral blood leukocytes were independent protective factors for coronary artery disease with a specific profile in different leukocyte subtypes. Clinical epigenetics. 2018;10:9.

25. Ichikawa K, Tomioka S, Suzuki Y, Nakamura R, Doi K, Yoshimura J, et al. Centromere evolution and CpG methylation during vertebrate speciation. Nature communications.
26. Indumathi B, Katkam SK, Krishna LSR, Kutala VK. Dual Effect of IL-6 -174 G/C Polymorphism and Promoter Methylation in the Risk of Coronary Artery Disease Among South Indians. Indian journal of clinical biochemistry: IJCB. 2019;34(2):180-7.

27. Heidari L, Ghaderian SMH, Vakili H, Salmani TA. Promoter methylation and functional variants in arachidonate 5-lipoxygenase and forkhead box protein O1 genes associated with coronary artery disease. Journal of cellular biochemistry. 2019;120(8):12360-8.

28. Liu Y, Reynolds LM, Ding J, Hou L, Lohman K, Young T, et al. Blood monocyte transcriptome and epigenome analyses reveal loci associated with human atherosclerosis. Nature communications. 2017;8(1):393.

29. Harada K, Shibata R, Ouchi N, Tokuda Y, Funakubo H, Suzuki M, et al. Increased expression of the adipocytokine omentin in the epicardial adipose tissue of coronary artery disease patients. Atherosclerosis. 2016;251:299-304.

30. Shibata Y, Kikuchi R, Ishii H, Suzuki S, Harada K, Hirayama K, et al. Balance between angiogenic and anti-angiogenic isoforms of VEGF-A is associated with the complexity and severity of coronary artery disease. Clinica chimica acta; international journal of clinical chemistry. 2018;478:114-9.

31. Li X, Ji Y, Kang J, Fang N. Association between blood neutrophil-to-lymphocyte ratio and severity of coronary artery disease: Evidence from 17 observational studies involving 7017 cases. Medicine. 2018;97(39):e12432.

32. Badin JK, Bruning RS, Sturek M. Effect of metabolic syndrome and aging on Ca(2+) dysfunction in coronary smooth muscle and coronary artery disease severity in Ossabaw miniature swine. Experimental gerontology. 2018;108:247-55.

33. Chen PY, Qin L, Baeyens N, Li G, Afolabi T, Budatha M, et al. Endothelial-to-
mesenchymal transition drives atherosclerosis progression. The Journal of clinical investigation. 2015;125(12):4514-28.

34. Al-Yafeai Z, Yurdagul A, Jr., Peretik JM, Alfaidi M, Murphy PA, Orr AW. Endothelial FN (Fibronectin) Deposition by alpha5beta1 Integrins Drives Atherogenic Inflammation. Arteriosclerosis, thrombosis, and vascular biology. 2018;38(11):2601-14.

35. Wang D, Wang Y, Ma J, Wang W, Sun B, Zheng T, et al. MicroRNA-20a participates in the aerobic exercise-based prevention of coronary artery disease by targeting PTEN. Biomedicine & pharmacotherapy. 2017;95:756-63.

36. Nariman-Saleh-Fam Z, Vahed SZ, Aghaee-Bakhtiari SH, Daraei A, Saadatian Z, Kafil HS, et al. Expression pattern of miR-21, miR-25 and PTEN in peripheral blood mononuclear cells of patients with significant or insignificant coronary stenosis. Gene. 2019;698:170-8.

37. Choquet K, Yang S, Moir RD, Forget D, Lariviere R, Bouchard A, et al. Absence of neurological abnormalities in mice homozygous for the Polr3a G672E hypomyelinating leukodystrophy mutation. Molecular brain. 2017;10(1):13.

Figures
Chromosome distributions of intragenic DMCs. Hypermethylated DMCs were marked in red, hypomethylated DMCs were marked in blue.
Identification of differentially expressed-methylated genes. (a) Venn plot of differentially expressed genes in dataset GSE42148 and differentially methylated genes in dataset GSE107143. (b, c) Representative heat map of the top 50 DEMGs in dataset GSE42148 and GSE107143.
Consolidation analysis results of gene region distribution of intragenic DMCs. (a) Bar plot for intragenic DMCs in different regions of DMGs. (b) Bar plot for intragenic DMCs in different regions of DEMGs. (c) Bar plot for intragenic DMCs in different regions of four DEMGs groups. (d) UpSet plot for intragenic DMCs in different regions of hypermethylated genes. (e) UpSet plot for intragenic DMCs in different regions of hypomethylated genes.
Figure 4

PPI network, top 3 modules and top 10 hub genes of 4 DEMGs groups. (a, b) Up-hyper genes. (c, d) Up-hypo genes. (e, f) Down-hyper genes. (g, h) Down-hypo genes.
GO functional enrichment analysis of top 10 hub genes of 4 DEMGs groups. (a) Up-hyper hub genes. (b) Up-hypo hub genes. (c) Down-hyper hub genes. (d) Down-hypo hub genes.
Figure 6

Relative mRNA expressions of top 1 hub genes from 4 DEMGs groups.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

Additional file 2.pdf
Additional file 1.pdf
Additional file 3.pdf